文献速递心脑血管急症

2015至2019年美国经颈动脉血运重建、经股动脉颈动脉支架置入与颈动脉内膜切除术的使用情况

Use of Transcarotid Artery Revascularization, Transfemoral Carotid Artery Stenting, and Carotid Endarterectomy in the US From 2015 to 2019.
PubMed 文献 · JAMA Netw Open · 2022-09-01
一句话结论2015至2019年美国颈动脉血运重建总例数增加,颈动脉内膜切除术比例下降,经颈动脉血运重建在高危患者中成为主导术式,超过经股动脉颈动脉支架置入和颈动脉内膜切除术。

该回顾性队列研究利用血管质量倡议数据库2015年1月1日至2019年12月31日数据,纳入108 676例因颈动脉狭窄行颈动脉内膜切除术、经股动脉颈动脉支架置入或经颈动脉血运重建的患者。总体以颈动脉内膜切除术最常见(75.0%),其次为经股动脉颈动脉支架置入(14.3%)和经颈动脉血运重建(10.7%)。2015年至2019年手术例数从16 754例增至27 269例(P < .001);颈动脉内膜切除术比例每年下降5.0%(95%CI -7.4%至-2.6%),经颈动脉血运重建每年增加5.3%(95%CI 2.3%至8.3%)。高危患者中变化更大:颈动脉内膜切除术每年下降7.8%(95%CI -11.9%至-3.8%),经股动脉颈动脉支架置入每年下降4.8%(95%CI -9.5%至-0.14%),经颈动脉血运重建每年增加12.6%(95%CI 7.1%至18.1%)。多分类逻辑回归显示患者危险状态是与经颈动脉血运重建(相较颈动脉内膜切除术和经股动脉颈动脉支架置入)最相关的特征;线性回归未发现手术年份与院内心肌梗死、卒中或死亡相关。

要点

  • 2015至2019年美国颈动脉血运重建总例数从16 754例增至27 269例(P < .001)。
  • 2015年颈动脉内膜切除术占84.9%、经股动脉颈动脉支架置入14.4%、经颈动脉血运重建0.8%;2019年分别为64.8%、13.3%、21.9%。
  • 颈动脉内膜切除术比例每年下降5.0%(95%CI -7.4%至-2.6%),经颈动脉血运重建每年增加5.3%(95%CI 2.3%至8.3%)。
  • 高危患者中经颈动脉血运重建每年增加12.6%(95%CI 7.1%至18.1%),颈动脉内膜切除术每年下降7.8%(95%CI -11.9%至-3.8%)。
  • 患者危险状态是与经颈动脉血运重建(相较颈动脉内膜切除术)最相关的特征(相对风险比36.10;95%CI 29.24-44.66;P < .001)。

适用人群与场景

  • 血管质量倡议数据库2015年1月1日至2019年12月31日期间因颈动脉狭窄行颈动脉内膜切除术、经股动脉颈动脉支架置入或经颈动脉血运重建的患者,共108 676例(平均[SD]年龄56.6[12.5]岁;男性66 684例[61.4%])。

研究设计与关键结果

  • 研究类型:回顾性队列研究,数据来自血管质量倡议数据库,纳入108 676例因颈动脉狭窄行颈动脉血运重建的患者。
  • 总体术式分布:颈动脉内膜切除术81 508例(75.0%),经股动脉颈动脉支架置入15 578例(14.3%),经颈动脉血运重建11 590例(10.7%)。
  • 手术例数从2015年16 754例增至2019年27 269例(P < .001)。
  • 2015年颈动脉内膜切除术占84.9%、经股动脉颈动脉支架置入占14.4%、经颈动脉血运重建占0.8%;2019年分别为64.8%、13.3%、21.9%。
  • 总体比例趋势:颈动脉内膜切除术每年下降5.0%(95%CI -7.4%至-2.6%),经颈动脉血运重建每年增加5.3%(95%CI 2.3%至8.3%)。
  • 高危患者比例趋势:颈动脉内膜切除术每年下降7.8%(95%CI -11.9%至-3.8%),经股动脉颈动脉支架置入每年下降4.8%(95%CI -9.5%至-0.14%),经颈动脉血运重建每年增加12.6%(95%CI 7.1%至18.1%)。
  • 多分类逻辑回归:患者危险状态是与经颈动脉血运重建(相较颈动脉内膜切除术)最相关的特征(相对风险比36.10;95%CI 29.24-44.66;P < .001),也是与经颈动脉血运重建(相较经股动脉颈动脉支架置入)最相关的特征(相对风险比14.10;95%CI 11.86-16.66;P < .001)。
  • 线性回归未发现手术年份与院内心肌梗死、卒中或死亡相关。

证据类型、等级与局限

  • 证据类型:回顾性队列研究,数据来自血管质量倡议数据库。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 研究结果显示,2015至2019年美国颈动脉血运重建总例数增加,颈动脉内膜切除术比例每年下降5.0%,经颈动脉血运重建比例每年增加5.3%,在高危患者中经颈动脉血运重建每年增加12.6%并超过经股动脉颈动脉支架置入和颈动脉内膜切除术。
  • 作者认为,患者高危状态是与支架置入方式相关的主要特征,突显了在该患者人群中颈动脉支架置入治疗被认为的重要性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: A transcarotid artery revascularization (TCAR) device was approved by the US Food and Drug Administration in 2015 for carotid revascularization in patients at high risk for stroke, cranial nerve injury, or major cardiac event. It is unclear how the introduction of TCAR has changed the use of carotid endarterectomy (CEA) and transfemoral carotid artery stenting (TFCAS).

OBJECTIVE: To quantify the temporal changes in the operative approach to carotid revascularization (CEA vs TFCAS vs TCAR), and to identify patient and disease characteristics commonly associated with each approach.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study obtained data from the Vascular Quality Initiative database from January 1, 2015, to December 31, 2019. Patients with carotid artery stenosis who underwent CEA, TFCAS, or TCAR were included. Data were analyzed from January to April 2022.

EXPOSURES: Month and year of surgery as well as patient risk status.

MAIN OUTCOMES AND MEASURES: Number and proportion of carotid revascularization procedures by operative approach.

RESULTS: A total of 108 676 patients (mean [SD] age 56.6 [12.5] years; 66 684 men [61.4%]) were included in the analysis. The most common operative approach overall was CEA (n = 81 508 [75.0%]), followed by TFCAS (n = 15 578 [14.3%]) and TCAR (n = 11 590 [10.7%]). The number of procedures increased over the study period (16 754 in 2015 vs 27 269 in 2019; P < .001). In 2015, CEA was used in 84.9% of all cases, followed by TFCAS (14.4%) and TCAR (0.8%). In 2019, CEA was used in 64.8% of cases, followed by TCAR (21.9%) and TFCAS (13.3%). The proportional use of CEA decreased by 5.0% (95% CI, -7.4% to -2.6%) per year, and TCAR use increased by 5.3% (95% CI, 2.3%-8.3%) per year. Among patients at high risk, the change was greater: CEA use decreased by 7.8% (95% CI, -11.9% to -3.8%) per year, TFCAS decreased by 4.8% (95% CI, -9.5% to -0.14%) per year, and TCAR increased by 12.6% (95% CI, 7.1%-18.1%) per year. Multinomial logistic regression showed that patient risk status was the most important characteristic associated with TCAR compared with CEA (relative risk ratio, 36.10; 95% CI, 29.24-44.66; P < .001) and TFCAS (relative risk ratio, 14.10; 95% CI, 11.86-16.66; P < .001). Linear regression revealed no association between year of surgery and in-hospital myocardial infarction, stroke, or mortality.

CONCLUSIONS AND RELEVANCE: Results of this study indicate that TCAR has become the dominant carotid revascularization approach, surpassing TFCAS and CEA in patients at high risk for stroke, cranial nerve injury, or cardiovascular events. Patient high-risk status was the main characteristic associated with a stenting approach, highlighting the perceived importance of carotid stenting therapies in this patient population.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Stonko DP, Goldsborough E, Kibrik P, et al. Use of Transcarotid Artery Revascularization, Transfemoral Carotid Artery Stenting, and Carotid Endarterectomy in the US From 2015 to 2019. JAMA Netw Open. 2022. PMID: 36112371. doi:10.1001/jamanetworkopen.2022.31944

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。